This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Order, S. E. Articles by Leichner, P. Search for Related Content PubMed PubMed Citation Articles by Order, S. E. Articles by Leichner, P.

Use of Isotopic Immunoglobulin in Therapy¹

Departments of Radiation Oncology and Immunology (S.E.O., J.L.K.), Medical Oncology (D.E.), Nuclear Medicine (P.A.), Radiological Sciences (S.S.), and Radiation Physics (P.L.), The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205

Antibodies raised in heterologous species against tumor-associated antigens such as ferritin and carcinoembryonic antigen may be utilized in diagnostic scanning and in cancer therapy. The radiolabeled (¹³¹I) antibodies have a mean effective half-life of 3 days. The tumor-bearing regions retain activity which was associated with objective evidence of remission in primary hepatic cancers. Major organ toxicity was not apparent in eight of nine patients treated with radioactive antibody. Objective evidence of clinical remission was documented by computer-assisted axial tomography scan remission in sequential studies that determine residual tumor in the same planar cuts. Future possible improvements in radioimmunoglobulin are discussed in light of the clinical findings.

¹ Presented at the UICC Workshop on Radioimmunodetection of Cancer, July 19 to 21, 1979, Lexington, Ky. Supported by NIH, National Cancer Institute, Grants CA-06973-16 and CA-25905-01.

² To whom requests for reprints should be addressed.